Normal view MARC view ISBD view

Antireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia. [Review]

MedStar author(s):

Citation: Surgical Clinics of North America. 101(3):391-403, 2021 Jun.PMID: 34048760Institution: MedStar Franklin Square Medical Center | MedStar Washington Hospital CenterDepartment: General Surgery Residency | Surgery/General SurgeryForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2021 Local holdings: Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1999 - February 2007ISSN:

0039-6109

Name of journal: The Surgical clinics of North AmericaAbstract: Barrett esophagus (BE), defined as intestinal metaplasia of the distal esophageal mucosa, typically results from chronic gastroesophageal reflux disease and is the only known precursor of esophageal adenocarcinoma. The standard of care for the management of early esophageal neoplasia in the setting of BE has changed drastically over the past 15 years. Further investigation into diagnostic and therapeutic adjuncts will continue to improve our ability to control or cure BE before its advancement to a life-threatening malignancy. Copyright (c) 2021 Elsevier Inc. All rights reserved.All authors: Fedorova E, Watson TJFiscal year: FY2021 Digital Object Identifier:

https://dx.doi.org/10.1016/j.suc.2021.03.002

Date added to catalog: 2021-06-28

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	34048760	Available		34048760

Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1999 - February 2007

Barrett esophagus (BE), defined as intestinal metaplasia of the distal esophageal mucosa, typically results from chronic gastroesophageal reflux disease and is the only known precursor of esophageal adenocarcinoma. The standard of care for the management of early esophageal neoplasia in the setting of BE has changed drastically over the past 15 years. Further investigation into diagnostic and therapeutic adjuncts will continue to improve our ability to control or cure BE before its advancement to a life-threatening malignancy. Copyright (c) 2021 Elsevier Inc. All rights reserved.

English